MAPS Raising Money for PTSD Research (Podcast)

Cannabis Radio News interviews Brad Burge of MAPS about current research into the therapeutic potential of psychedelics and marijuana,  how scientific research is reducing the stigma surrounding psychedelics, and the inspiring momentum of MAPS’ Legalizing Psychedelic Therapy crowdfunding campaign on Indiegogo. “It looks like we are going to be able to reach our goal, and maybe, if we get enough support, go beyond it,” explains Burge. “I think it’s a major step forward for public education about what these substances are and can do.” 

Listen to the interview here.

The Multidisciplinary Association for Psychedelic Studies, or MAPS, won federal approval in March to conduct “whole plant” research on marijuana with the goal of making an FDA approved prescription drug for PTSD suffers, the first such research approval in history. MAPS is also undertaking an eight-year, $18.5 million plan to make MDMA into a federally approved PTSD medicine by 2021. To find out more about MAPS and efforts to develop psychedelic therapy into a legal prescription treatments, CRN’s Brian Bahouth spoke with MAPS Director of Communications, Brad Burge.